In a report released yesterday, Mohit Bansal from Wells Fargo maintained a Buy rating on Gilead Sciences (GILD – Research Report), with a price ...
Diversify Advisory Services LLC trimmed its stake in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 16.3% during the ...
In a report released on January 21, Brian Abrahams from RBC Capital maintained a Hold rating on Gilead Sciences (GILD – Research Report), with ...
Gilead Sciences Inc (GILD) stock saw a modest uptick, ending the day at $92.96 which represents a slight increase of $1.12 or 1.22% from the prior close of $91.84. The stock opened at $92.06 and ...
Galapagos NV. announced its plans to split into two listed entities by mid-2025 by spinning off its activities focused on ...
The global precision diagnostics and medicine market, valued at US$132.46 billion in 2023, is forecasted to grow at a robust CAGR of ...
So far, the FDA has approved the drug only for people who already have HIV that’s resistant to other treatments. But its ...
Hosted on MSN5d
UNAIDS Calls On Leaders At Davos To Commit To Rapid Global Access To Revolutionary New Long-Acting HIV MedicinesUNAIDS urges speed and compassion urging pharmaceutical companies to enable access to new, life-saving medicines DAVOS/GENEVA, 21 January 2025—Today, at the World Economic Forum’s annual meeting in ...
Global leaders must urgently prioritise and work to provide access to new long-acting HIV prevention -- and potentially ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback